Matt's Take Matthew Herper The coronavirus exposes our health care system’s weaknesses. We can be stronger
Matt's Take Matthew Herper STAT Plus: Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough
Matt's Take Matthew Herper The debate over America’s drug-pricing system is built on myths. It’s time to face reality
Matt's Take Matthew Herper STAT Plus: The Senate’s drug pricing bill is an inevitable solution. It will still have plenty of unintended consequences
Matt's Take Matthew Herper STAT Plus: Can we really get better Covid vaccines? There are big hurdles, but some hope
Matt's Take Matthew Herper STAT Plus: Why Biogen’s Medicare mess is bad for the pharmaceutical industry
Matt's Take Matthew Herper STAT Plus: Robert Califf is a fervent believer in data. At the FDA, will that be enough?
Matt's Take Matthew Herper The Biden administration wants scientific advisers. It just doesn’t like what they have to say
Matt's Take Matthew Herper STAT Plus: By approving Biogen’s Alzheimer’s drug, the FDA is shifting its rules. That is a giant risk
Matt's Take Matthew Herper Having pandemic panic attacks about virus variants? National preparation is the cure
Matt's Take Matthew Herper Biden’s plan to end policy of keeping Covid vaccine doses in reserve is the first step in a difficult journey
Matt's Take Matthew Herper Antibody drugs seem to work. But the virus is moving faster than we can make them
Matt's Take Matthew Herper The lesson from Trump catching Covid-19: With this virus, there are no magic bullets
Matt's Take Matthew Herper Eager for a Covid vaccine, Trump now trusts drug companies he previously vilified
Matt's Take Matthew Herper People are dying from coronavirus because we’re not fast enough at clinical research
Matt's Take Matthew Herper The U.S. gets a D- in the coronavirus fight. That stands for ‘disorganization,’ and it’s fixable
Matt's Take Matthew Herper Coronavirus testing is starting to get better — but it has a long way to go
Biotech Adam Feuerstein and Matthew Herper STAT Plus: STAT’s guide to the most important, beneficial drugs approved in the past decade